Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 11 | 2023 | 423 | 2.490 |
Why?
|
| Esophageal Neoplasms | 8 | 2023 | 39 | 2.040 |
Why?
|
| Pleural Effusion, Malignant | 4 | 2021 | 8 | 1.630 |
Why?
|
| Oncolytic Virotherapy | 2 | 2021 | 16 | 1.330 |
Why?
|
| Adenocarcinoma | 5 | 2021 | 297 | 1.110 |
Why?
|
| Pneumonectomy | 6 | 2020 | 12 | 0.940 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 907 | 0.920 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2021 | 108 | 0.890 |
Why?
|
| HMGB1 Protein | 6 | 2020 | 11 | 0.810 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2020 | 14 | 0.810 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 99 | 0.770 |
Why?
|
| Tomography | 1 | 2022 | 5 | 0.750 |
Why?
|
| Neuropilin-2 | 1 | 2022 | 2 | 0.740 |
Why?
|
| Interferon-gamma | 5 | 2020 | 59 | 0.730 |
Why?
|
| Appendicitis | 2 | 2012 | 15 | 0.710 |
Why?
|
| Appendectomy | 2 | 2012 | 19 | 0.710 |
Why?
|
| Humans | 41 | 2025 | 32274 | 0.710 |
Why?
|
| Reperfusion Injury | 6 | 2012 | 60 | 0.710 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 31 | 0.700 |
Why?
|
| Viruses | 1 | 2021 | 4 | 0.680 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 6 | 0.680 |
Why?
|
| Oncolytic Viruses | 1 | 2021 | 8 | 0.680 |
Why?
|
| Interferon Regulatory Factor-1 | 5 | 2012 | 7 | 0.670 |
Why?
|
| Interleukin-2 | 1 | 2020 | 38 | 0.660 |
Why?
|
| Hepatocytes | 6 | 2012 | 80 | 0.660 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3624 | 0.650 |
Why?
|
| Internship and Residency | 2 | 2021 | 319 | 0.650 |
Why?
|
| Coculture Techniques | 1 | 2020 | 78 | 0.640 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 52 | 0.640 |
Why?
|
| Analgesia | 1 | 2020 | 29 | 0.640 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 461 | 0.570 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 199 | 0.550 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 252 | 0.540 |
Why?
|
| Endosonography | 2 | 2015 | 55 | 0.540 |
Why?
|
| Neoplasms | 2 | 2025 | 754 | 0.540 |
Why?
|
| Mice | 13 | 2022 | 2571 | 0.530 |
Why?
|
| Male | 30 | 2025 | 19437 | 0.480 |
Why?
|
| Female | 23 | 2025 | 19942 | 0.480 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 762 | 0.470 |
Why?
|
| Esophagogastric Junction | 1 | 2015 | 10 | 0.460 |
Why?
|
| Liver | 5 | 2012 | 492 | 0.450 |
Why?
|
| Aged | 16 | 2025 | 10260 | 0.430 |
Why?
|
| Hospital Costs | 2 | 2012 | 48 | 0.430 |
Why?
|
| Middle Aged | 17 | 2025 | 11848 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 381 | 0.420 |
Why?
|
| Animals | 16 | 2022 | 8199 | 0.380 |
Why?
|
| Hospitals | 2 | 2025 | 95 | 0.370 |
Why?
|
| Efficiency, Organizational | 1 | 2011 | 16 | 0.350 |
Why?
|
| Thymus Neoplasms | 3 | 2020 | 6 | 0.350 |
Why?
|
| Operating Rooms | 1 | 2011 | 41 | 0.340 |
Why?
|
| Postoperative Complications | 4 | 2025 | 823 | 0.340 |
Why?
|
| Lymph Nodes | 3 | 2020 | 113 | 0.330 |
Why?
|
| Gallbladder Diseases | 1 | 2009 | 8 | 0.300 |
Why?
|
| Immunotherapy | 2 | 2021 | 91 | 0.300 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2009 | 21 | 0.300 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 242 | 0.290 |
Why?
|
| Esophagectomy | 3 | 2022 | 15 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 157 | 0.280 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 180 | 0.280 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 109 | 0.280 |
Why?
|
| Clinical Competence | 2 | 2021 | 330 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 3898 | 0.250 |
Why?
|
| Adult | 9 | 2025 | 9256 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 792 | 0.240 |
Why?
|
| Patient Readmission | 1 | 2025 | 135 | 0.210 |
Why?
|
| Body Composition | 2 | 2023 | 327 | 0.210 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 71 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 63 | 0.190 |
Why?
|
| Retinal Vein Occlusion | 1 | 2022 | 2 | 0.190 |
Why?
|
| Lung | 2 | 2023 | 263 | 0.190 |
Why?
|
| Neuropilin-1 | 1 | 2022 | 12 | 0.180 |
Why?
|
| Cell Nucleus | 4 | 2010 | 111 | 0.180 |
Why?
|
| Protein Isoforms | 1 | 2022 | 60 | 0.180 |
Why?
|
| Subcutaneous Fat | 1 | 2022 | 44 | 0.180 |
Why?
|
| Thymoma | 2 | 2012 | 7 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 258 | 0.180 |
Why?
|
| Gulf War | 1 | 2021 | 1 | 0.180 |
Why?
|
| Vehicle Emissions | 1 | 2021 | 4 | 0.170 |
Why?
|
| Macrophages, Alveolar | 1 | 2021 | 11 | 0.170 |
Why?
|
| Feedback | 1 | 2021 | 41 | 0.170 |
Why?
|
| Truth Disclosure | 1 | 2021 | 14 | 0.170 |
Why?
|
| Pneumonia | 1 | 2021 | 62 | 0.170 |
Why?
|
| Liver Transplantation | 3 | 2012 | 185 | 0.170 |
Why?
|
| Vaccinia virus | 1 | 2020 | 19 | 0.170 |
Why?
|
| Lymphatic System | 1 | 2020 | 3 | 0.160 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2020 | 1 | 0.160 |
Why?
|
| Credentialing | 1 | 2020 | 7 | 0.160 |
Why?
|
| Adenoma | 1 | 2021 | 34 | 0.160 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 7 | 0.160 |
Why?
|
| Receptors, CCR7 | 1 | 2020 | 4 | 0.160 |
Why?
|
| Tumor Burden | 2 | 2019 | 63 | 0.160 |
Why?
|
| Exercise Therapy | 1 | 2023 | 250 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 164 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2020 | 39 | 0.160 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 44 | 0.160 |
Why?
|
| Lactic Acid | 1 | 2020 | 56 | 0.160 |
Why?
|
| Carcinoma | 1 | 2021 | 92 | 0.160 |
Why?
|
| Oxidative Stress | 3 | 2011 | 255 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 54 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2022 | 320 | 0.160 |
Why?
|
| Veterans | 1 | 2020 | 64 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 99 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 77 | 0.150 |
Why?
|
| United States | 4 | 2020 | 4072 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 131 | 0.150 |
Why?
|
| Curriculum | 1 | 2021 | 203 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 14 | 0.150 |
Why?
|
| Stress, Physiological | 1 | 2020 | 56 | 0.150 |
Why?
|
| Survival Rate | 5 | 2020 | 893 | 0.150 |
Why?
|
| Prognosis | 4 | 2020 | 1534 | 0.150 |
Why?
|
| Mitochondrial Proteins | 2 | 2011 | 72 | 0.150 |
Why?
|
| Liver Diseases | 2 | 2010 | 72 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 68 | 0.150 |
Why?
|
| Time Factors | 4 | 2018 | 2204 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 179 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 502 | 0.150 |
Why?
|
| Cisplatin | 2 | 2009 | 78 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2020 | 204 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 183 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 79 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2011 | 243 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2020 | 1425 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2012 | 299 | 0.140 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 171 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2020 | 461 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2022 | 3416 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 2648 | 0.130 |
Why?
|
| Algorithms | 1 | 2021 | 536 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 395 | 0.130 |
Why?
|
| Cognition | 1 | 2021 | 547 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2020 | 355 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1083 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 48 | 0.120 |
Why?
|
| Cells, Cultured | 4 | 2011 | 839 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 34 | 0.120 |
Why?
|
| Cell Membrane | 1 | 2016 | 109 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2016 | 79 | 0.120 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 168 | 0.110 |
Why?
|
| Risk Factors | 5 | 2025 | 3934 | 0.110 |
Why?
|
| Thymectomy | 2 | 2012 | 3 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 595 | 0.110 |
Why?
|
| Acetylation | 2 | 2011 | 14 | 0.110 |
Why?
|
| Pennsylvania | 3 | 2025 | 80 | 0.100 |
Why?
|
| Length of Stay | 2 | 2012 | 321 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 2240 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2020 | 2316 | 0.100 |
Why?
|
| SEER Program | 1 | 2012 | 38 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 43 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 33 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 471 | 0.080 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2011 | 11 | 0.080 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 74 | 0.080 |
Why?
|
| Histone Deacetylase 1 | 1 | 2010 | 3 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 46 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 8 | 0.080 |
Why?
|
| Natural Killer T-Cells | 1 | 2010 | 3 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 187 | 0.080 |
Why?
|
| Nitrites | 1 | 2009 | 22 | 0.080 |
Why?
|
| Lymph Node Excision | 2 | 2020 | 94 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2009 | 33 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 4 | 2009 | 65 | 0.070 |
Why?
|
| Gene Expression | 4 | 2012 | 345 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1179 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 83 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2009 | 236 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2020 | 368 | 0.070 |
Why?
|
| Sepsis | 1 | 2009 | 164 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2008 | 82 | 0.060 |
Why?
|
| Pregnancy | 1 | 2009 | 961 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 1840 | 0.060 |
Why?
|
| Rats | 4 | 2009 | 1895 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2025 | 137 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2010 | 215 | 0.050 |
Why?
|
| Adolescent | 1 | 2012 | 3517 | 0.050 |
Why?
|
| Registries | 1 | 2025 | 294 | 0.050 |
Why?
|
| Gene Knockout Techniques | 2 | 2016 | 16 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 773 | 0.050 |
Why?
|
| Apoptosis | 3 | 2010 | 375 | 0.050 |
Why?
|
| Macrophages | 2 | 2019 | 207 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2016 | 183 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 52 | 0.050 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2022 | 9 | 0.050 |
Why?
|
| Fundus Oculi | 1 | 2022 | 13 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 125 | 0.050 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2021 | 15 | 0.040 |
Why?
|
| Adenoviridae | 2 | 2012 | 68 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 51 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 55 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2010 | 10 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2010 | 20 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 44 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 305 | 0.040 |
Why?
|
| Cell Line | 2 | 2011 | 454 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 11 | 0.040 |
Why?
|
| Rats, Inbred Lew | 2 | 2009 | 123 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 28 | 0.040 |
Why?
|
| Monocytes | 1 | 2020 | 141 | 0.040 |
Why?
|
| Cytokines | 1 | 2020 | 237 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2010 | 454 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2010 | 193 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 553 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2009 | 224 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 555 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 28 | 0.030 |
Why?
|
| Inflammation Mediators | 2 | 2009 | 96 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 477 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 2016 | 3 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 897 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 443 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 81 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 252 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 543 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 729 | 0.030 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 108 | 0.020 |
Why?
|
| E2F1 Transcription Factor | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 170 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 651 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 112 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 47 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 86 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 288 | 0.020 |
Why?
|
| Galactosylceramides | 1 | 2010 | 1 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 324 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 246 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 94 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 308 | 0.020 |
Why?
|
| Cecum | 1 | 2009 | 10 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2009 | 3 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2009 | 7 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2009 | 36 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2009 | 31 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 38 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 64 | 0.020 |
Why?
|
| Nitrates | 1 | 2009 | 29 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2009 | 60 | 0.020 |
Why?
|
| Abdomen | 1 | 2009 | 44 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 121 | 0.020 |
Why?
|
| Autophagy | 1 | 2009 | 55 | 0.020 |
Why?
|
| Hepatitis | 1 | 2009 | 9 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 200 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 188 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 79 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 140 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 499 | 0.020 |
Why?
|
| Myocardium | 1 | 2009 | 184 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2009 | 121 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2009 | 186 | 0.020 |
Why?
|
| Oxygen | 1 | 2009 | 138 | 0.020 |
Why?
|
| Disease | 1 | 2008 | 5 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2008 | 24 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2008 | 30 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 717 | 0.020 |
Why?
|
| Regeneration | 1 | 2008 | 178 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 408 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 727 | 0.010 |
Why?
|